Cargando…

Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis

OBJECTIVE—Cardiac fibrosis is an important component of diabetic cardiomyopathy. Peroxisome proliferator–activated receptor γ (PPARγ) ligands repress proinflammatory gene expression, including that of osteopontin, a known contributor to the development of myocardial fibrosis. We thus investigated th...

Descripción completa

Detalles Bibliográficos
Autores principales: Caglayan, Evren, Stauber, Bradley, Collins, Alan R., Lyon, Christopher J., Yin, Fen, Liu, Joey, Rosenkranz, Stephan, Erdmann, Erland, Peterson, Leif E., Ross, Robert S., Tangirala, Rajendra K., Hsueh, Willa A.
Formato: Texto
Lenguaje:English
Publicado: American Diabetes Association 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518499/
https://www.ncbi.nlm.nih.gov/pubmed/18511847
http://dx.doi.org/10.2337/db07-0924
_version_ 1782158578600116224
author Caglayan, Evren
Stauber, Bradley
Collins, Alan R.
Lyon, Christopher J.
Yin, Fen
Liu, Joey
Rosenkranz, Stephan
Erdmann, Erland
Peterson, Leif E.
Ross, Robert S.
Tangirala, Rajendra K.
Hsueh, Willa A.
author_facet Caglayan, Evren
Stauber, Bradley
Collins, Alan R.
Lyon, Christopher J.
Yin, Fen
Liu, Joey
Rosenkranz, Stephan
Erdmann, Erland
Peterson, Leif E.
Ross, Robert S.
Tangirala, Rajendra K.
Hsueh, Willa A.
author_sort Caglayan, Evren
collection PubMed
description OBJECTIVE—Cardiac fibrosis is an important component of diabetic cardiomyopathy. Peroxisome proliferator–activated receptor γ (PPARγ) ligands repress proinflammatory gene expression, including that of osteopontin, a known contributor to the development of myocardial fibrosis. We thus investigated the hypothesis that PPARγ ligands could attenuate cardiac fibrosis. RESEARCH DESIGN AND METHODS—Wild-type cardiomyocyte- and macrophage-specific PPARγ(−/−) mice were infused with angiotensin II (AngII) to promote cardiac fibrosis and treated with the PPARγ ligand pioglitazone to determine the roles of cardiomyocyte and macrophage PPARγ in cardiac fibrosis. RESULTS—Cardiomyocyte-specific PPARγ(−/−) mice (cPPARγ(−/−)) developed spontaneous cardiac hypertrophy with increased ventricular osteopontin expression and macrophage content, which were exacerbated by AngII infusion. Pioglitazone attenuated AngII-induced fibrosis, macrophage accumulation, and osteopontin expression in both wild-type and cPPARγ(−/−) mice but induced hypertrophy in a PPARγ-dependent manner. We pursued two mechanisms to explain the antifibrotic cardiomyocyte-PPARγ–independent effects of pioglitazone: increased adiponectin expression and attenuation of proinflammatory macrophage activity. Adenovirus-expressed adiponectin had no effect on cardiac fibrosis and the PPARγ ligand pioglitazone did not attenuate AngII-induced cardiac fibrosis, osteopontin expression, or macrophage accumulation in monocyte-specific PPARγ(−/−) mice. CONCLUSIONS—We arrived at the following conclusions: 1) both cardiomyocyte-specific PPARγ deficiency and activation promote cardiac hypertrophy, 2) both cardiomyocyte and monocyte PPARγ regulate cardiac macrophage infiltration, 3) inflammation is a key mediator of AngII-induced cardiac fibrosis, 4) macrophage PPARγ activation prevents myocardial macrophage accumulation, and 5) PPARγ ligands attenuate AngII-induced cardiac fibrosis by inhibiting myocardial macrophage infiltration. These observations have important implications for potential interventions to prevent cardiac fibrosis.
format Text
id pubmed-2518499
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher American Diabetes Association
record_format MEDLINE/PubMed
spelling pubmed-25184992009-09-01 Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis Caglayan, Evren Stauber, Bradley Collins, Alan R. Lyon, Christopher J. Yin, Fen Liu, Joey Rosenkranz, Stephan Erdmann, Erland Peterson, Leif E. Ross, Robert S. Tangirala, Rajendra K. Hsueh, Willa A. Diabetes Complications OBJECTIVE—Cardiac fibrosis is an important component of diabetic cardiomyopathy. Peroxisome proliferator–activated receptor γ (PPARγ) ligands repress proinflammatory gene expression, including that of osteopontin, a known contributor to the development of myocardial fibrosis. We thus investigated the hypothesis that PPARγ ligands could attenuate cardiac fibrosis. RESEARCH DESIGN AND METHODS—Wild-type cardiomyocyte- and macrophage-specific PPARγ(−/−) mice were infused with angiotensin II (AngII) to promote cardiac fibrosis and treated with the PPARγ ligand pioglitazone to determine the roles of cardiomyocyte and macrophage PPARγ in cardiac fibrosis. RESULTS—Cardiomyocyte-specific PPARγ(−/−) mice (cPPARγ(−/−)) developed spontaneous cardiac hypertrophy with increased ventricular osteopontin expression and macrophage content, which were exacerbated by AngII infusion. Pioglitazone attenuated AngII-induced fibrosis, macrophage accumulation, and osteopontin expression in both wild-type and cPPARγ(−/−) mice but induced hypertrophy in a PPARγ-dependent manner. We pursued two mechanisms to explain the antifibrotic cardiomyocyte-PPARγ–independent effects of pioglitazone: increased adiponectin expression and attenuation of proinflammatory macrophage activity. Adenovirus-expressed adiponectin had no effect on cardiac fibrosis and the PPARγ ligand pioglitazone did not attenuate AngII-induced cardiac fibrosis, osteopontin expression, or macrophage accumulation in monocyte-specific PPARγ(−/−) mice. CONCLUSIONS—We arrived at the following conclusions: 1) both cardiomyocyte-specific PPARγ deficiency and activation promote cardiac hypertrophy, 2) both cardiomyocyte and monocyte PPARγ regulate cardiac macrophage infiltration, 3) inflammation is a key mediator of AngII-induced cardiac fibrosis, 4) macrophage PPARγ activation prevents myocardial macrophage accumulation, and 5) PPARγ ligands attenuate AngII-induced cardiac fibrosis by inhibiting myocardial macrophage infiltration. These observations have important implications for potential interventions to prevent cardiac fibrosis. American Diabetes Association 2008-09 /pmc/articles/PMC2518499/ /pubmed/18511847 http://dx.doi.org/10.2337/db07-0924 Text en Copyright © 2008, American Diabetes Association https://creativecommons.org/licenses/by-nc-nd/3.0/Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
spellingShingle Complications
Caglayan, Evren
Stauber, Bradley
Collins, Alan R.
Lyon, Christopher J.
Yin, Fen
Liu, Joey
Rosenkranz, Stephan
Erdmann, Erland
Peterson, Leif E.
Ross, Robert S.
Tangirala, Rajendra K.
Hsueh, Willa A.
Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis
title Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis
title_full Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis
title_fullStr Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis
title_full_unstemmed Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis
title_short Differential Roles of Cardiomyocyte and Macrophage Peroxisome Proliferator–Activated Receptor γ in Cardiac Fibrosis
title_sort differential roles of cardiomyocyte and macrophage peroxisome proliferator–activated receptor γ in cardiac fibrosis
topic Complications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2518499/
https://www.ncbi.nlm.nih.gov/pubmed/18511847
http://dx.doi.org/10.2337/db07-0924
work_keys_str_mv AT caglayanevren differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT stauberbradley differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT collinsalanr differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT lyonchristopherj differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT yinfen differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT liujoey differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT rosenkranzstephan differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT erdmannerland differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT petersonleife differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT rossroberts differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT tangiralarajendrak differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis
AT hsuehwillaa differentialrolesofcardiomyocyteandmacrophageperoxisomeproliferatoractivatedreceptorgincardiacfibrosis